Evidence map›Paper›PMID 38372748›Full record

ArticleCellular and molecular life sciences : CMLS2024

KIF18A inactivates hepatic stellate cells and alleviates liver fibrosis through the TTC3/Akt/mTOR pathway.

Hao Zhang, Tong Xia, Zhijia Xia, Huaxin Zhou, Zhipeng Li, Wei Wang, Xiangyu Zhai, Bin Jin

Abstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hao Zhang *Organ Transplant Department, Qilu Hospital of Shandong University, Jinan, China.
Tong Xia *Organ Transplant Department, Qilu Hospital of Shandong University, Jinan, China.
Zhijia XiaDepartment of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich, Munich, Germany.
Huaxin ZhouDepartment of Hepatobiliary Surgery, The Second Hospital of Shandong University, Jinan, China.
Zhipeng LiDepartment of Hepatobiliary Surgery, The Second Hospital of Shandong University, Jinan, China.
Wei WangMedical Integration and Practice Center, Shandong University, Jinan, China. jinglewei@sdu.edu.cn.
Xiangyu ZhaiOrgan Transplant Department, Qilu Hospital of Shandong University, Jinan, China. xiangyuzhai@126.com.ORCID http://orcid.org/0000-0001-7603-5769
Bin JinOrgan Transplant Department, Qilu Hospital of Shandong University, Jinan, China. jinbin9449@126.com.

Funding

the Second Hospital of Shandong University Cultivation Funding No.2022YP45
6 · The paper itself

Abstract

Activation of hepatic stellate cells (HSCs) has been demonstrated to play a pivotal role in the process of liver fibrogenesis. In this study, we observed a decrease in the expression of KIF18A in fibrotic liver tissues compared to healthy liver tissues, which exhibited a negative correlation with the activation of HSCs. To elucidate the molecular mechanisms underlying the involvement of KIF18A, we performed in vitro proliferation experiments and established a CCl4-induced liver fibrosis model. Our results revealed that KIF18A knockdown enhanced HSCs proliferation and reduced HSCs apoptosis in vitro. Mouse liver fibrosis grade was evaluated with Masson's trichrome and alpha-smooth muscle actin (α-SMA) staining. In addition, the expression of fibrosis markers Col1A1, Stat1, and Timp1 were detected. Animal experiments demonstrated that knockdown of KIF18A could promote liver fibrosis, whereas overexpression of KIF18A alleviated liver fibrosis in a CCl4-induced mouse model. Mechanistically, we found that KIF18A suppressed the AKT/mTOR pathway and exhibited direct binding to TTC3. Moreover, TTC3 was found to interact with p-AKT and could promote its ubiquitination and degradation. Our findings provide compelling evidence that KIF18A enhances the protein binding between TTC3 and p-AKT, promoting TTC3-mediated ubiquitination and degradation of p-AKT. These results refine the current understanding of the mechanisms underlying the pathogenesis of liver fibrosis and may offer new targets for treating this patient population.

Indexed as

Hepatic Stellate CellsKinesinsLiver CirrhosisAnimalsHumansMiceProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesUbiquitin-Protein LigasesKIF18a protein, mouseKinesinsProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesUbiquitin-Protein LigasesAKTHSCsKIF18ALiver fibrosismTOR pathwayTTC3

Identifiers

PMID38372748
PMCPMC10876760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.